logo
From Local to Landmark: Scientologists Dedicate the Historical Site of the First Dianetics Foundation

From Local to Landmark: Scientologists Dedicate the Historical Site of the First Dianetics Foundation

ELIZABETH, N.J., June 5, 2025 /PRNewswire/ — The location where Dianetics author and Scientology Founder L. Ron Hubbard established the first Foundation 75 years ago reopens to the world, restored and dedicated as a historical Landmark Site.
Nestled in a quiet part of Elizabeth, New Jersey, is an unassuming, three-story building—a structure that once unquestionably became the nexus of a global awakening.
Just 15 miles from New York City, this rejuvenated Colonial-Revival setting at 42 Aberdeen Road now joins the distinguished ranks of L. Ron Hubbard (LRH) Landmark Sites around the world.
During a spring afternoon celebration attended by Scientologists, community leaders and restoration specialists, guests weren't just honoring a historic moment. In fact, they were able to take the very first steps inside the exact rooms where Mr. Hubbard had personally taught the first Dianetics auditors, delivered the first Dianetics lectures and set in motion the first Dianetics Research Foundation.
'To be here, at this historic site on L. Ron Hubbard's path of discovery, is an honor and in a class of its own,' one guest said.
Now completely restored to its 1950 appearance, 42 Aberdeen Road is more than a building, it is the precise cornerstone where the world first turned a page and a revolution of the human mind all began.
With the May 9, 1950 publication of Dianetics: The Modern Science of Mental Health, what unfolded within these walls was nothing short of explosive—as the book began its unprecedented run of 28 weeks on the New York Times bestseller list. Almost overnight, crowds from across America began arriving without invitation, eager to meet and learn in person from the author of what was rapidly becoming the most popular book ever written on the human mind.
This site of universal influence now stands as it once did—complete with original furniture, vintage crystal doorknobs and refinished wood floors with mahogany Celtic pattern inlays. All have been restored to their glorious past, including the desk where Mr. Hubbard once wrote and the fireplace before which students gathered.
The Remington typewriter and SoundScriber dictation recorders Mr. Hubbard worked with are also on display—even his prized Ford Deluxe 'Woody' Wagon is parked outside.
Officiating the ceremony was the Church of Scientology Preservationist who oversaw the meticulous restoration. 'This site became the epicenter of a movement—one that grew from Dianetics, the first workable science of the mind, into the Scientology religion, with Churches and Missions spanning the globe,' he said. 'And for the first time, beginning today, you will be able to walk inside and stand right where it all began!'
Fittingly, and just days before the 75th Anniversary of the publication of Dianetics, dignitaries honoring the site's Grand Opening spoke of the impact of L. Ron Hubbard, both locally and globally.
The day's first guest speaker, Ms. Jennifer Costa, President and CEO of the Greater Elizabeth Chamber of Commerce, welcomed the opening as a milestone for the city. 'Here in Elizabeth, we pride ourselves on a theme that we think says everything: 'It all starts here.' And that is so very true. Elizabeth is a city of many firsts—from the first capital of the state of New Jersey to the home of our first governor and even the first submarine. Well, today we stand here in front of this breathtaking site, another first that claims Elizabeth with pride as the very place where the first Dianetics Foundation was born. We can't wait to welcome all of you to this landmark that belongs to all of us—because this is where your history and our history meet—right here at 42 Aberdeen Road.'
Mr. Thomas B. Connolly, who served as historical architect on the project, emphasized the importance of preserving the site's original character. 'Working with your team to restore this landmark was a dream. Your commitment to quality and authenticity was evident from day one and your goal was clear: to return the site to exactly how it was when Mr. Hubbard was here. As just a single example, when we peeled back the white aluminum siding that had been on the façade for decades, we uncovered a century-old surprise: the original cedar shingles, right where they had been since 1910.' Mr. Connolly added, 'And that's only one of the countless details that brought this heritage site back to life, transforming it into what you see today: the gem of the block!'
Dr. Apostle Lemmew Samuel, Founder of an Evangelical Assembly in New York City, has spent a lifetime in religious service—and spoke to the spiritual power of the Landmark Site. 'Just like those first readers who drove here back in 1950 to learn from Mr. L. Ron Hubbard himself, I now find myself on the same doorstep, drawn by the same truth from the pages of Dianetics,' Dr. Samuel said. 'I'm just getting started with Dianetics. But I know I have in my hands a way to help the people I serve—couples in crisis, youth searching for direction, anyone trying to hold their life together. I can help them find their way out of the darkness of the mind and into the light!'
Dr. Monica Sanchez, a United Nations Cultural Ambassador and Humanitarian, spoke not just of the legacy of this storied location, but of the enduring imprint L. Ron Hubbard left on Mankind. 'Sometimes we think we know the way, until life gives you a detour—one without signs. But Mr. Hubbard's work says: Here's another road. Here's the best road. That's why I call L. Ron Hubbard a GPS for humanity,' she said to the crowd. 'If I had been here on Aberdeen Road back in 1950, I would have told him: 'Take me as your student!' I would have felt very privileged just to learn by his side. But, thanks to everything he left behind and your incredible work to preserve it, we can all be his students.'
Captain Steve Nagiewicz, Executive Director Emeritus of the world-famous Explorers Club—where Mr. Hubbard was an exalted member and carried three official expedition flags—praised LRH's work as nothing short of bold discovery. 'Mr. Hubbard explored the oceans, he crossed continents, he set a course for distant stars. But his final frontier was the most uncharted territory of all: conducting a journey inside the human mind,' he said. 'Exploring the unknown, living on the edge, going where no one has gone before … it requires a rock-solid state of mind, leaving no margin for error.' Mr. Nagiewicz added, 'It's my hope that this day and this site will always remind us to push farther, reach deeper, keep exploring. And as future explorers venture to the stars, no doubt L. Ron Hubbard will be with them in spirit!'
Historic 42 Aberdeen Road has a sister in Bay Head, New Jersey, 50 miles away, where LRH wrote Dianetics. Mr. Hubbard worked in both locations during the same time period, in Bay Head for part of the year and Elizabeth for the other. The Bay Head property was previously opened as an L. Ron Hubbard Landmark Site in 2011—Mr. Hubbard's centennial year.
All told, there are seven such Landmark Sites now open on three continents around the world, including L. Ron Hubbard's heritage site at the base of Camelback Mountain in Phoenix, Arizona—known as the Birthplace of Scientology; the original Founding Church that Mr. Hubbard established in Washington, DC; the original Hubbard Communications Office on Fitzroy Street in London, England; his Linksfield Ridge estate overlooking Johannesburg, South Africa; and his headquarters at Saint Hill in East Grinstead, England.
Each Landmark Site offers a literal and visual history of the work and advances Mr. Hubbard achieved during the time he was at that particular location. Each also features a room devoted to the wider story of Mr. Hubbard's life of global exploration and research—including his revolutionary work here in Elizabeth, New Jersey. In full, the sites mark Mr. Hubbard's progressive steps to the founding of Dianetics and Scientology.
Two more Landmark Sites are set to open by this summer—one in the US and another in Southern Africa—carrying forward the legacy of places like 42 Aberdeen Road, a global tribute that echoes for generations to come.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Children's Hospital of Philadelphia and Children's Hospital Colorado Researchers Conduct First Prospective Study of Pediatric EoE Patients and Disease Progression
Children's Hospital of Philadelphia and Children's Hospital Colorado Researchers Conduct First Prospective Study of Pediatric EoE Patients and Disease Progression

Malaysian Reserve

time4 days ago

  • Malaysian Reserve

Children's Hospital of Philadelphia and Children's Hospital Colorado Researchers Conduct First Prospective Study of Pediatric EoE Patients and Disease Progression

Study found that stiffness of the esophagus could serve as an important biomarker for disease progression and indicate which patients may benefit the most from current therapies PHILADELPHIA, Aug. 15, 2025 /PRNewswire/ — Researchers from Children's Hospital of Philadelphia (CHOP) and Children's Hospital Colorado have found that better control of chronic eosinophilic esophagitis (EoE)-associated inflammation during childhood leads to less stiffening of the esophagus, resulting in fewer disease complications. Using Endoluminal functional imaging (FLIP), the study team suggests this could be a key marker for assessing disease severity and progression. The findings were published online today by the journal Gastroenterology. EoE is a chronic allergic inflammatory disease of the esophagus, the muscular tube that carries food from the throat to the stomach. Children can experience nausea, regurgitation, vomiting, abdominal pain and a burning feeling like acid reflux. They may also have difficulty swallowing and gag frequently. Often, they can experience dysphagia, which is when it feels like something is stuck in their throat. If EoE goes untreated, the esophagus may narrow because of scarring, a phenomenon known as stricture. Chronic EoE-associated inflammation can lead to progressive tissue remodeling and fibrostenosis, or the narrowing of the esophagus. While clinicians recognize the severity of the disease, long-term studies looking at disease progression over time, and the impact of controlling the disease from a young age, is relatively unknown. 'This is the first study to follow kids overtime (with these endoscopic assessments) and evaluate the patients who are at the highest risk of complications,' said co-senior study author Amanda Muir, MD, a pediatric gastroenterologist in the Division of Gastroenterology, Hepatology and Nutrition at CHOP. 'With the recent FDA approval of two medications for EoE, having this data could help identify the patients who could benefit from these therapies the most and observe improvement at a histologic level over time.' Researchers at CHOP and Children's Hospital Colorado launched a longitudinal study to evaluate long-term changes in esophageal distensibility, or the ability of the esophagus to expand, in pediatric patients between the ages of 3 and 18 years old. Symptomatic, endoscopic and histologic data were collected at each visit during the study. A total of 112 patients with EoE were included with a median follow-up time of 11 months, some followed for over 4 years. 'Following children living with EoE over time has given us a clearer picture of how inflammation affects the esophagus and how treating it can improve the esophagus and outcomes for patients,' said Calies Menard-Katcher, MD, co-senior study author and Associate Director of Clinical Research for the Gastrointestinal Eosinophilic Diseases Program at Children's Hospital Colorado. 'It's exciting to see these results confirm what we've suspected in caring for patients — and they may even help us spot those at risk for more severe disease.' The study found that patients with tissue samples showing a response to treatment demonstrated the most improvement in distensibility over time. After adjusting for different factors, the study found that patients with lower esophageal distensibility had increased odds of patient-reported dysphagia, or difficulty swallowing. Patients with fibrostenosis were generally diagnosed at an older age, had the disease for a longer period and showed reduced esophageal distensibility at baseline predicted the need for future dilation in patients with strictures. The authors suggest that further studies that examine the disease from a molecular level could help them understand which patients may be at highest risk of severe disease and could benefit from a variety of treatment strategies. This study was supported by the National Institutes of Health grants R01DK124266-01, K23DK109263 and R21TR003039. Kennedy et al, 'Histologic response is associated with improved esophageal distensibility and symptom burden in pediatric eosinophilic esophagitis.' Gastroenterology. Online August 15, 2025. DOI: 10.1053/ About Children's Hospital of Philadelphia:A non-profit, charitable organization, Children's Hospital of Philadelphia was founded in 1855 as the nation's first pediatric hospital. Through its long-standing commitment to providing exceptional patient care, training new generations of pediatric healthcare professionals, and pioneering major research initiatives, the hospital has fostered many discoveries that have benefited children worldwide. Its pediatric research program is among the largest in the country. The institution has a well-established history of providing advanced pediatric care close to home through its CHOP Care Network, which includes more than 50 primary care practices, specialty care and surgical centers, urgent care centers, and community hospital alliances throughout Pennsylvania and New Jersey. CHOP also operates the Middleman Family Pavilion and its dedicated pediatric emergency department in King of Prussia, the Behavioral Health and Crisis Center (including a 24/7 Crisis Response Center) and the Center for Advanced Behavioral Healthcare, a mental health outpatient facility. Its unique family-centered care and public service programs have brought Children's Hospital of Philadelphia recognition as a leading advocate for children and adolescents. For more information, visit ABOUT CHILDREN'S HOSPITAL COLORADO Children's Hospital Colorado is one of the nation's leading and most expansive nonprofit pediatric healthcare systems with a mission to improve the health of children through patient care, education, research and advocacy. Founded in 1908 and ranked among the best children's hospitals in the nation as recognized by U.S. News & World Report, Children's Colorado has established itself as a pioneer in the discovery of innovative and groundbreaking treatments that are shaping the future of pediatric healthcare worldwide. Children's Colorado offers a full spectrum of family-centered care at its urgent, emergency and specialty care locations throughout Colorado, including an academic medical center on the Anschutz Medical Campus in Aurora, hospitals in Colorado Springs, Highlands Ranch and Broomfield, and outreach clinics across the region. For more information, visit or connect with us on Facebook, Instagram and YouTube. Contact: Ben LeachChildren's Hospital of Philadelphia(609)634-7906leachb@

Fermi America™ and ASP Isotopes Join Forces to Secure America's Advanced Reactor Fuel Supply
Fermi America™ and ASP Isotopes Join Forces to Secure America's Advanced Reactor Fuel Supply

Malaysian Reserve

time4 days ago

  • Malaysian Reserve

Fermi America™ and ASP Isotopes Join Forces to Secure America's Advanced Reactor Fuel Supply

–Texas-based private grid campus to host one of the first U.S. HALEU enrichment facilities, strengthening energy security and reducing reliance on foreign sources AMARILLO, Texas, Aug. 15, 2025 /PRNewswire/ — Fermi America, developer of the 11 GW private grid campus for next-generation hyperscale AI in collaboration with the Texas Tech University System, today announced it has signed a Memorandum of Understanding (MOU) with ASP Isotopes Inc. (NASDAQ: ASPI) and its subsidiary Quantum Leap Energy LLC (QLE) to explore the development of a High Assay Low Enriched Uranium (HALEU) enrichment facility at Fermi America's site in Carson County, Texas. The planned facility would use advanced laser-based isotope separation technology to produce HALEU — a specialized nuclear fuel essential for many Generation IV and small modular reactor (SMR) designs. With very few commercial HALEU suppliers currently operating in the Western world, the project is intended to strengthen U.S. and allied supply chains, reduce reliance on Russian enrichment, and accelerate the deployment of advanced nuclear technologies. Fermi America's private grid campus will be anchored by four AP1000® nuclear units using conventional fuel, with the potential to integrate advanced reactor technologies in future phases. The addition of domestic HALEU production capability would position the private grid as both a significant clean energy generator and a strategic nuclear fuel hub. 'Our nation's ability to lead in advanced nuclear energy is directly tied to our capacity to fuel it here at home,' said Toby Neugebauer, Co-Founder and CEO, Fermi America. 'This decision helps ensure that America's next generation of nuclear reactors will be powered by American innovation, technology, and resolve.' 'This collaboration represents a decisive step toward securing the nuclear fuel needed for the next wave of advanced reactors,' said Mesut Uzman, Chief Nuclear Construction Officer, Fermi America. 'It reinforces our mission to build the most advanced, resilient, and secure private grid in the world.' 'Advanced reactors cannot be built without HALEU, and our Quantum Enrichment™ technology is designed to deliver it with speed, precision, and environmental responsibility,' said Paul Mann, Chairman and CEO, ASP Isotopes Inc. 'Partnering with Fermi America gives us the platform and location to play a central role in the emerging Western HALEU market.' 'Energy security is national security,' said Rick Perry, Co-Founder of Fermi America and former U.S. Secretary of Energy. 'This project will help America control its own destiny in nuclear power, create jobs here in Texas, and send a clear message that the United States intends to lead – not follow – in the race for advanced, carbon-free energy.' According to the U.S. Department of Energy, U.S. HALEU demand could exceed 50 metric tons annually by 2035, with similar needs emerging in Europe and Asia. The proposed project would help meet this demand, supporting the clean energy transition while enhancing energy security. For media inquiries, please contact:Lexi Swearingen[email protected] About Fermi America Fermi America is pioneering the development of next-generation electric grids that deliver highly redundant power at gigawatt scale, essential for enabling next-generation artificial intelligence. Co-founded by former U.S. Energy Secretary Rick Perry, Fermi America's behind-the-meter HyperGrid campus will integrate the largest nuclear power complex in America, the nation's biggest combined-cycle natural gas project, utility grid power, solar power, and battery energy storage. About the Texas Tech University SystemEstablished in 1996, the Texas Tech University System is one of the top public university systems in the nation, consisting of five universities – Texas Tech University, Texas Tech University Health Sciences Center, Angelo State University, Texas Tech University Health Sciences Center El Paso and Midwestern State University. Headquartered in Lubbock, Texas, the TTU System is a more than $3 billion enterprise focused on advancing higher education, health care, research and outreach with approximately 21,000 employees and 64,000 students, more than 400,000 alums, a statewide economic impact of $19.2 billion and an endowment valued at $3 billion. In its short history, the TTU System has grown tremendously and is nationally acclaimed, operating at 20 academic locations in 16 cities (15 in Texas, 1 international). In addition, the TTU System is one of only nine in the nation to offer programs for undergraduate, medical, law, nursing, pharmacy, dental and veterinary education, among other academic areas. About ASP Isotopes Isotopes Inc. (NASDAQ: ASPI) is an advanced materials company dedicated to the production of enriched isotopes for use in multiple industries, including nuclear energy, medicine, semiconductors, and quantum computing. Through its subsidiary Quantum Leap Energy, ASPI is developing Quantum Enrichment™ technology to produce HALEU fuel and other critical isotopes at lower cost, faster, and with no radioactive waste. Forward-Looking StatementsThis press release may contain 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding our strategy, future operations, financial position, prospects, plans and objectives of management. In some cases, you can identify forward-looking statements because they contain words such as 'may,' 'will,' 'will be,' 'will likely result,' 'should,' 'expects,' 'plans,' 'anticipates,' 'could,' 'would,' 'foresees,' 'intends,' 'target,' 'projects,' 'contemplates,' 'believes,' 'estimates,' 'predicts,' 'potential,' 'outlook,' or 'continue' or the negative of these words or other similar terms or expressions. These forward-looking statements are not guarantees of future performance, but are based on management's current expectations, assumptions, and beliefs concerning future developments and their potential effect on us, which are inherently subject to uncertainties, risks and changes in circumstances that are difficult to predict. Our expectations expressed or implied in these forward-looking statements may not turn out to be correct. Our results could be materially different from our expectations because of various risks.

Ultima Genomics' ppmSeq™ Delivers Unmatched Combination of Sensitivity and Efficiency for Whole-Genome MRD Detection
Ultima Genomics' ppmSeq™ Delivers Unmatched Combination of Sensitivity and Efficiency for Whole-Genome MRD Detection

Malaysian Reserve

time5 days ago

  • Malaysian Reserve

Ultima Genomics' ppmSeq™ Delivers Unmatched Combination of Sensitivity and Efficiency for Whole-Genome MRD Detection

New bioRxiv paper showcases: Tumor-informed ctDNA detection down to one-in-ten million (10-7), which extends well beyond the limits of currently available clinical minimal residual disease (MRD) assays Superior double-stranded DNA (dsDNA) recovery rates versus other technologies, reducing sequencing requirements by 10- to 100-fold to achieve ultrasensitive detection levels and enabling a cost-effective whole-genome approach High efficiency and simple WGS workflow, yielding greater than 20x coverage per ng of cfDNA, reducing the amount of input material required for MRD and other liquid biopsy applications New highly sensitive approach to tumor-informed MRD as well as tumor-naive MRD and monitoring settings, where matched tumor tissue is not available FREMONT, Calif., Aug. 14, 2025 /PRNewswire/ — Ultima Genomics, a developer and manufacturer of an innovative ultra-high throughput sequencing architecture, announced a new publication, made available today in bioRxiv, showing the ultra-sensitive single-nucleotide variant (SNV) detection capabilities of its ppmSeq™ technology, with error rates down to 8 x 10-8. Led by researchers from the Landau Lab at Weill Cornell Medicine and the New York Genome Center, this pre-print also demonstrates ctDNA detection limits for ppmSeq which significantly extends beyond the limits of currently available MRD assays, while utilizing a simple whole genome sequencing workflow that requires 10- to 100-fold less sequencing coverage versus other error correction techniques. These researchers conclude that these key features make ppmSeq well suited for clinical applications where high accuracy is required for mutation identification, such as tumor informed and tumor agnostic MRD detection. 'With its unique combination of low-cost and high accuracy, ppmSeq marks a real breakthrough in sequencing technology,' said Dan A. Landau, MD, PhD, a core member at the New York Genome Center, and Professor of Medicine & Professor of Physiology and Biophysics at Weill Cornell Medicine. 'It opens new horizons in studying the somatic genome as a novel frontier in human genetics, and holds enormous promise for clinical applications, including sensitive detection of cancer residual disease.' While high-throughput sequencing has seen rapid adoption for genome-wide variant identification, distinguishing true biological variation in the form of SNVs from sequencing errors remains a key challenge. Traditional sequencing approaches are too error-prone for detection of low variant allele frequency variants and are blind to errors resulting from DNA degradation or damage during sample preparation. These challenges limit the ability of traditional NGS technologies to detect and identify rare variants, a feature which is important in emerging applications like MRD and somatic mosaicism. To increase the ability to detect rare variants, current NGS approaches often rely on error-correction techniques, such as duplex sequencing, which involves sequencing both strands of a DNA molecule to filter out errors identified by discordant strands caused by single-stranded damage. While this reduces SNV error rates for dual-stranded reads, singleton reads must be discarded for these methods. As such, these methods require massive over sequencing to reliably capture sufficient duplex molecules, making whole-genome duplex sequencing prohibitively expensive. In a Nature Methods paper published in 2025, researchers in the Landau Lab demonstrated the advantages identifying SNVs with Ultima's flow-based sequencing by synthesis technology versus conventional SBS chemistry. Researchers identified that the ultra-low error profiles of Ultima's flow-based sequencing chemistry presented a foundation on which to build error correction techniques using duplex sequencing that could potentially enable ultra-low ctDNA detection levels, meaningful for applications that require rare mutation detection like MRD. In this new bioRxiv paper, researchers from the same group utilized ppmSeq, a technology developed by Ultima and native to the Ultima platform, to further improve upon the previously published low SNV detection limits. Building on Ultima's ultra-low error, flow-based sequencing, ppmSeq encodes both strands of DNA molecules in a single sequencing read to enable up to part-per-ten million (10-7) accuracy (SNVQ70) for SNV calling. This exceptional accuracy provides extreme assay sensitivity for low frequency alleles while also requiring 10- to 100-fold less sequencing depth than other error correction techniques. Study showcases ppmSeq as a highly accurate, low-cost, high throughput method for dsDNA sequencing built on a simple WGS workflow with potential for robust clinical applications Researchers from the Landau Lab at Weill Cornell Medicine and the New York Genome Center benchmarked ppmSeq assay performance and sensitivity against other technologies. Key findings demonstrate ppmSeq has: Ultrasensitive SNV detection capabilities. ppmSeq demonstrated ultrasensitive SNV detection with error rates down to 0.8 x 10-7 (0.8 parts-per-ten million) for gDNA and cell-free DNA. Superior dsDNA recovery rates and lower sequencing requirements. ppmSeq demonstrated superior double-stranded DNA (dsDNA) recovery rates, reducing sequencing requirements by 10- to 100-fold and enabling a cost-effective whole genome approach. Ability to sequence low-input samples. The ppmSeq workflow was shown to be highly efficient, yielding greater than 20x coverage per ng of cfDNA and reducing the amount of input material required. Researchers also tested the capabilities of ppmSeq in clinical applications by assessing circulating tumor DNA (ctDNA) detection for disease monitoring in cancer patients. Key findings include: Tumor-informed ctDNA detection down to one-in-ten million. ppmSeq enabled tumor-informed ctDNA detection of 10-5 across multiple cancers, and up to 10-7 in cancers with high mutation burden at 30x sequencing depth, which extends below the limits of current MRD assays. ctDNA detection capabilities in tumor-naive disease monitoring. ppmSeq identified disease-specific signal in plasma cell-free DNA without the need for a matched tumor. Together, these researchers conclude that ppmSeq is a highly accurate and cost-effective option for emerging clinical applications including tumor-informed MRD, tumor-naïve MRD and an opportunity to explore new whole-genome applications in cancer genomics, including somatic mosaicism. 'As a highly accurate, highly scalable WGS approach, ppmSeq can be a key building block for the next generation of tumor-informed and tumor-naive cancer monitoring applications' said Adam Widman, MD, a researcher and medical oncologist at Memorial Sloan Kettering Cancer Center and a co-author on the study. 'ppmSeq is a major step forward in high-accuracy sequencing,' said Charles Swanton, Deputy Clinical Director at The Francis Crick Institute. 'Its low error rate and high throughput could enable powerful new applications in liquid biopsy and beyond. This study showcases how ultra-low error, high-throughput sequencing with ppmSeq could transform applications in the field of MRD requiring very high accuracy — from bench to bedside.' Ultima's ppmSeq technology enables high-quality data and its published specifications provide part-per-million accuracy, or SNVQ60, for calling single nucleotide variants (SNVs). ppmSeq, designed for the UG 100 sequencing platform, is also compatible with the UG 100 Solaris Free workflow. Launched at AGBT 2025, the UG 100 Solaris workflows enabled an over 50% increase versus prior specifications in output to 10 to 12 billion reads per wafer and pricing reduced by 20% to $0.24 per million reads, enabling the $80 genome. 'Ultima's unique sequencing architecture was designed to specifically meet the needs of cost-effective, large-scale applications. It especially excels in applications like liquid biopsy that require extreme accuracy, and we are excited to see further validation of ppmSeq within the academic community,' said Gilad Almogy, CEO and Founder of Ultima Genomics. 'We believe that sensitivity, ease of workflow and low cost of ppmSeq will be transformational for applications requiring earlier detection such as MRD.' The full study, 'Paired plus-minus sequencing is an ultra-high throughput and accurate method for dual strand sequencing of DNA molecules' is now available in bioRxiv. About Ultima Genomics Ultima Genomics is unleashing the power of genomics at scale. The Company's mission is to continuously drive the scale of genomic information to enable unprecedented advances in biology and improvements in human health. With humanity on the cusp of a biological revolution, there is a virtually endless need for more genomic information to address biology's complexity and dynamic change—and a further need to challenge conventional next-generation sequencing technologies. Ultima's revolutionary new sequencing architecture drives down the costs of sequencing to help overcome the tradeoffs that scientists and clinicians are forced to make between the breadth, depth and frequency with which they use genomic information. The new sequencing architecture was designed to scale far beyond conventional sequencing technologies, lower the cost of genomic information and catalyze the next phase of genomics in the 21st century. To learn more, visit Media Contact Vikki Herrera for Ultima Genomics408-206-7009vikki@

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store